Enzymology
Exploiting the vulnerable active site of a copper-only superoxide dismutase to disrupt fungal pathogenesisInhibiting the vulnerable active site of copper-only SODs

https://doi.org/10.1074/jbc.RA118.007095Get rights and content
Under a Creative Commons license
open access

Copper-only superoxide dismutases (SODs) represent a new class of SOD enzymes that are exclusively extracellular and unique to fungi and oomycetes. These SODs are essential for virulence of fungal pathogens in pulmonary and disseminated infections, and we show here an additional role for copper-only SODs in promoting survival of fungal biofilms. The opportunistic fungal pathogen Candida albicans expresses three copper-only SODs, and deletion of one of them, SOD5, eradicated candidal biofilms on venous catheters in a rodent model. Fungal copper-only SODs harbor an irregular active site that, unlike their Cu,Zn-SOD counterparts, contains a copper co-factor unusually open to solvent and lacks zinc for stabilizing copper binding, making fungal copper-only SODs highly vulnerable to metal chelators. We found that unlike mammalian Cu,Zn-SOD1, C. albicans SOD5 indeed rapidly loses its copper to metal chelators such as EDTA, and binding constants for Cu(II) predict that copper-only SOD5 has a much lower affinity for copper than does Cu,Zn-SOD1. We screened compounds with a variety of indications and identified several metal-binding compounds, including the ionophore pyrithione zinc (PZ), that effectively inhibit C. albicans SOD5 but not mammalian Cu,Zn-SOD1. We observed that PZ both acts as an ionophore that promotes uptake of toxic metals and inhibits copper-only SODs. The pros and cons of a vulnerable active site for copper-only SODs and the possible exploitation of this vulnerability in antifungal drug design are discussed.

copper
yeast
superoxide dismutase (SOD)
superoxide ion
fungi
Candida
Cu-only SOD
metalloenzyme
mycocide
virulence

Cited by (0)

This work was supported, in whole or in part, by National Institutes of Health Grants RO1GM50016 and RO1 AI119949 (to V. C. C.), R01 AI073289 (to D. R. A.), F31 DK111114 (to E. M. C.), and F32 GM112320 (to R. L. P.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

This article contains Table S1.

1

Supported by National Institutes of Health Grant K08 AI108727, Burroughs Wellcome Fund Grant 1012299, and Doris Duke Charitable Foundation Grant 112580130.